This open-access review explores the application of artificial intelligence and text mining technologies to advance understanding of the female reproductive system. By leveraging AI-driven analysis of biomedical literature and data, the research enables the development of multiscale computational models that bridge molecular, cellular, and physiological processes. The work demonstrates how these technologies facilitate personalized medicine approaches tailored to individual patient needs and biological variations. This integration of AI and biomedical modeling represents a significant advancement in reproductive health research, offering new opportunities for improved diagnostics, treatment strategies, and patient outcomes.

Cervical non-invasive vagus nerve stimulation (nVNS) has emerged as a practical neuromodulation approach with FDA clearance for primary headache disorders, yet questions persist regarding its efficacy. This comprehensive review synthesizes anatomical, biophysical, physiological, and clinical evidence demonstrating that nVNS reliably activates vagal pathways without surgical intervention. The analysis encompasses cervical vagus anatomy, biophysical mechanisms supporting target engagement, and computational modeling confirming recruitment of myelinated vagal fibers. Converging evidence from functional imaging, electrophysiology, immune studies, and autonomic biomarkers reveals consistent modulation of canonical vagal projection sites and parasympathetic activation. Sham-controlled randomized trials in cluster headache and migraine demonstrate nVNS superiority over placebo in both acute and preventive outcomes with favorable safety profiles, establishing a robust mechanistic and clinical foundation for this therapeutic approach.

Digital twins represent a paradigm shift in clinical trial methodology by enabling AI-generated virtual patient models trained on historical data to predict patient responses under control conditions. This innovation challenges the longstanding requirement for live placebo arms, reducing trial sizes, compressing timelines, and lowering costs while minimizing patient exposure to ineffective treatments. With regulatory validation from both the EMA and FDA, alongside real-world implementation by pharmaceutical leaders like Sanofi, digital twin technology has transitioned from theoretical to practical application. These individual-level computational models generate statistically valid comparative evidence without full randomization to placebo, fundamentally transforming drug development efficiency and ethical patient outcomes.

The integration of multiomics technologies with artificial intelligence represents a transformative paradigm in precision medicine and drug discovery. By combining genomic, transcriptomic, proteomic, and metabolomic analyses with advanced deep learning algorithms, researchers can decipher complex biological datasets and identify disease patterns with unprecedented precision. This synergistic approach accelerates target identification, optimizes lead compounds, and enhances clinical trial design across diverse therapeutic areas including oncology and neurodegenerative diseases. While challenges regarding data harmonization, reproducibility, and algorithmic bias remain, multiomics-AI integration enables hypothesis generation and data-driven discovery that fundamentally advances translational medicine. This convergence provides distinct competitive advantages in virtual screening, pharmacokinetic modeling, and safety assessment, heralding a new era in evidence-based therapeutic development.

This article from the Journal of Chest Surgery examines the application of organoids in cancer research. Organoids, three-dimensional tissue structures that recapitulate organ architecture and function, represent a significant advancement in cancer modeling and therapeutic development. The publication explores how organoid technology provides improved platforms for studying tumor biology, drug response, and personalized medicine approaches. By bridging the gap between traditional two-dimensional cell cultures and in vivo animal models, organoids enable researchers to investigate cancer mechanisms more accurately while reducing reliance on animal testing. The article discusses the role of organoids in advancing precision oncology and their potential to enhance treatment outcomes in thoracic malignancies, contributing to the evolving landscape of cancer research methodologies.

Accurately predicting the outcome of drug candidates remains a central challenge in preclinical research. Traditionally, this has relied on the use of 2D cell cultures or animal models. In recent decades, significant efforts have been made to develop 3D in vitro models that better recapitulate in vivo physiology, while also minimizing the use of animal testing. In this report, we discuss spheroids, organoids, organ-on-chips, and scaffolds as well as assess their relevance as models for heart, gut, brain, liver, and tumor tissue. It appears that spheroids are uniquely appropriate for modeling tumors, where features like hypoxia - typically a limitation of 3D models - mirror the natural tumor microenvironment. The human heart, gut, brain and liver are complex organs that are still difficult to model with conventional methods; in these tissues, 3D models such as organoids and organ-on-chips appear to be the most physiologically accurate alternative. Across all these models, scaffolds and hydrogels play a central role in mimicking the native extracellular matrix and promoting physiologically relevant cell behaviour. 

Examine how digital twins in clinical trials function as virtual control arms. This report reviews FDA guidance, AI models, and implementation requirements.

Portions plus petites, protéines en extra… Les médicaments pour la perte de poids étant de plus en plus répandus, les restaurants américains modifient leur offre pour répondre aux besoins de leurs clients.

Le fast-track national a pour objectif de réduire significativement les délais d’évaluation des demandes d’autorisation, tout en garantissant la qualité et la rigueur éthique et scientifique de l’évaluation. Ce dispositif pilote s’adresse aux essais mononationaux de phase I ou de phase I/II intégrées, répondant à au moins l’un des critères suivants : Maladies graves, rares ou invalidantes pour lesquelles aucun traitement approprié n’existe ; Premier essai dans une classe thérapeutique (avec un mécanisme d’action entièrement nouveau) ; Inclusion d’adolescents (12 à 18 ans) dans des essais chez l’adulte.

Organoids and Organ-on-a-Chip technology have been considered a paradigm shift in cell culture for over a decade. However, fundamental usability and logistics aspects have hampered widespread adoption, as both require deep biological expertise and cumbersome logistics of cell materials. MIMETAS has invested in productization of organoids in its perfused high throughput OrganoPlate platform. Its OrganoReady® product line comprises of 64 adult stem cell derived colon organoids grown as perfused tubules that are delivered ready-to-use to the bench of the scientist. Turnkey assays allow monitoring of barrier function under toxic and inflammatory challenges. New products for the kidney are available in early access, and next generation models comprising fully vascularized, stroma and immune competent liver, lung and tumor tissues are available in a services setting.

Aging is a multifactorial process driven by core mechanisms: cellular damage, epigenetic alterations, and immunosenescence. Immunotherapy addresses core aging drivers with high specificity and durability. Cutting-edge immunotherapies for senescent cell clearance show robust preclinical efficaey. Critical translational challenges include insufficient target specificity, species differences, and unclear long-term safety.

TLC's tLNP CAR-T platform represents an innovative advancement in immunotherapy, utilizing targeted lipid nanoparticles to deliver CAR-encoding mRNA directly into T cells through in vivo administration. This approach eliminates the complexity and cost associated with traditional ex vivo cell manipulation and chemotherapy preconditioning, significantly improving safety and accessibility. By enabling off-the-shelf, redosable treatments without personalized manufacturing, the technology addresses critical scalability challenges in current CAR-T therapies. Currently in preclinical development, tLNP CAR-T demonstrates substantial potential to expand treatment options for cancer and autoimmune diseases, offering faster, safer, and more repeatable therapeutic solutions to a broader patient population globally.

3D bioprinting technology represents a transformative approach in precision oncology by enabling the reconstruction of complex tumor microenvironments with programmable precision. This review examines how 3D-bioprinted tumor organoids facilitate the development of sophisticated in vitro models that accurately recapitulate the cellular and extracellular components of native tumors. By allowing researchers to control spatial organization and composition of tumor structures, this technology enhances drug testing, therapeutic screening, and personalized medicine applications. The integration of bioprinting with oncology research provides unprecedented opportunities for understanding tumor biology, improving treatment efficacy, and reducing reliance on traditional animal models, thereby accelerating the translation of laboratory findings into clinical practice.

Cellular senescence sits at the intersection of at least half of the recognized hallmarks of aging, functioning as both an upstream driver and a downstream consequence. Senescent cells accumulate because induction rates rise while immune clearance declines with age, and their SASP output drives the chronic low-grade inflammation underlying nearly every age-related disease.

This research presents a Unified Agent Lifecycle Management (UALM) framework designed to address governance challenges in healthcare organizations deploying agentic AI systems. As autonomous AI agents proliferate across clinical workflows—supporting documentation and patient monitoring—institutions increasingly struggle with agent sprawl, accountability gaps, and inconsistent security controls. The authors developed a five-layer governance architecture coupled with a maturity model linking measurable key performance indicators to operational thresholds. Using Monte Carlo simulations across three healthcare organization sizes under varying governance conditions, the study evaluates UALM's effectiveness against baseline and existing frameworks like NIST AI RMF-Lite. By establishing systematic lifecycle management protocols and KPI-driven accountability mechanisms, this framework provides healthcare systems with practical operational guidance for managing distributed AI agent fleets while maintaining regulatory compliance and clinical safety.

Researchers conducted ex vivo drug screening on bladder cancer tissues from 38 patients to predict treatment responses and personalize therapeutic strategies. The study screened sensitivity to 15 agents, including standard chemotherapies and experimental compounds, achieving a 75.9% methodological success rate within clinically practical four-day timeframes. Analysis revealed distinct drug and tumor clusters, with drug resistance correlating to aggressive clinical features and specific mutations. Cross-resistance between agents was prevalent, and cisplatin-resistant tumors exhibited diverse mutational profiles with varying multi-drug resistance patterns. These findings suggest ex vivo screening on patient tissue samples could provide actionable clinical insights for tailored bladder cancer treatment selection, addressing the disease's high treatment failure rates.

Drug screening based on in-vitro primary tumor cell culture has demonstrated potential in personalized cancer diagnosis. However, the limited number of tumor cells, especially from patients with early stage cancer, has hindered the widespread application of this technique. Hence, we developed a digital microfluidic system for drug screening using primary tumor cells and established a working protocol for precision medicine. Smart control logic was developed to increase the throughput of the system and decrease its footprint to parallelly screen three drugs on a 4 × 4 cm2 chip in a device measuring 23 × 16 × 3.5 cm3. We validated this method in an MDA-MB-231 breast cancer xenograft mouse model and liver cancer specimens from patients, demonstrating tumor suppression in mice/patients treated with drugs that were screened to be effective on individual primary tumor cells.

The global next-generation bioelectronic medicine device market was valued at $3.6 billion in 2025 and is projected to reach $10.8 billion by 2034, expanding at a compound annual growth rate (CAGR) of 13.7% over the forecast period from 2026 to 2034, driven by accelerating clinical validation of neuroimmune modulation therapies, rising chronic disease burden, and transformative regulatory milestones including the first-ever FDA approval of a vagus nerve stimulator for rheumatoid arthritis. Bioelectronic medicine -- the discipline of using precisely targeted electrical impulses to modulate the peripheral and central nervous systems for therapeutic benefit -- has emerged as one of the most disruptive frontiers in medical technology, offering a potential alternative or complement to biologics and pharmaceutical interventions for autoimmune, inflammatory, and neurological conditions. As of 2026, the market is being reshaped by a new generation of devices that integrate miniaturized implants, wireless power and data transfer, and AI-adaptive stimulation algorithms, enabling closed-loop therapies that dynamically respond to real-time physiological signals.

This review examines in vivo immune engineering through mRNA therapeutics to reprogram the cardiac microenvironment following myocardial infarction. Myocardial infarction triggers a biphasic immune response that critically determines whether the heart undergoes adaptive repair or develops pathological fibrosis. Traditional drug and gene therapy delivery systems have proven inadequate for precisely modulating this complex temporal and spatial sequence. Nucleoside-modified messenger RNA encapsulated within lipid nanoparticles has emerged as a promising platform for delivering transient, non-integrating, and repeatable immune modulation to damaged cardiac tissue. The article synthesizes interdisciplinary advancements in mRNA technology and cardiac immunology, exploring mRNA design strategies and nucleoside modifications to optimize therapeutic outcomes.

Chimeric antigen receptor T-cell therapy represents a transformative advancement in cancer immunotherapy, yet conventional ex vivo approaches encounter significant manufacturing complexity, elevated production costs, and quality control challenges. In vivo CAR-T therapy medicinal products utilizing viral vectors or lipid nanoparticle platforms offer substantial promise by streamlining manufacturing, improving scalability, and reducing costs while broadening patient accessibility. However, these innovations introduce potential risks including off-target effects and immunogenicity concerns. This article examines the technological progress and regulatory framework surrounding in vivo CAR-T products, analyzing manufacturability advantages and safety considerations. The authors propose adaptive regulatory strategies coupled with early regulatory engagement and international coordination to facilitate clinical translation and standardized deployment of these emerging therapeutic modalities.